Change - Announcement of Cessation::Resignation of Executive Director and Chief Executive Officer

Issuer & Securities

Issuer/ Manager
PHARMESIS INTERNATIONAL LTD.
Securities
PHARMESIS INTERNATIONAL LTD. - SG1BH6000003 - BFK
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
02-Jan-2018 17:18:44
Status
New
Announcement Sub Title
Resignation of Executive Director and Chief Executive Officer
Announcement Reference
SG180102OTHRF058
Submitted By (Co./ Ind. Name)
Mr Wu Xuedan
Designation
Executive Director
Description (Please provide a detailed description of the event in the box below)
Resignation of Executive Director and Chief Executive Officer

Additional Details

Name Of Person
Jiang Yun
Age
55
Is effective date of cessation known?
Yes
If yes, please provide the date
31/12/2017
Detailed Reason (s) for cessation
To pursue personal interest.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of Appointment to current position
15/01/2015
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
2
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
1
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director, Chief Executive Officer and a member of Nominating Committee
Role and responsibilities
The duties, role and responsibilities of the Executive Director, Chief Executive Officer and member of Nominating Committee.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Nil
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Mr. Jiang Yun is deemed interested in the 49% shareholding in the Company's indirect subsidiary, Sichuan Longlife Pharmaceutical Co. Ltd.
Past (for the last 5 years)
Sichuan Neautus Traditional Chinese Medicine Co., Ltd.
Present
1. Chengdu Kinna Investment Co Ltd;
2. Sichuan Neautus Traditional Chinese Medicine Decoction Pieces Holding Co Ltd;
3. Sichuan Province Neautus Traditional Chinese Medicine Processing Engineering Research Co Ltd;
4. Sichuan Neautus Ecological Herbs Co Ltd;
5. Jiangyou Zhangming Neautus Aconite Co. Ltd;
6. Tianjin Neautus Traditional Chinese Medicine (Sichuan) Co. Ltd;
7. EYS Neautus Traditional Chinese Medicine (Sichuan) Co. Ltd;
8. EYS Neautus (Hong Kong) Co. Ltd;
9. Sichuan Yili Pharmaceutical Trading Co Ltd